AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Inclusion Criteria include: 1. Diagnosis type I Diabetes Mellitus for at least 12 months 2. Receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months 3. Fasting C-peptide concentration ≤8.5% (≤69 mmol/mol) at screening 4. BMI 18.5-35.0 kg/m2 Exclusion Criteria include: 1. known or suspected hypersensitivity to Investigational Medicinal Products 2. clinically significant concomitant disease or abnormal lab values 3. supine systolic BP outside range 95-140 mmHg and/or diastolic BP greater than 90 mmHg